China Universal Asset Management Co. Ltd. Has $718,000 Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

China Universal Asset Management Co. Ltd. grew its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 87.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 19,866 shares of the specialty pharmaceutical company's stock after buying an additional 9,267 shares during the quarter. China Universal Asset Management Co. Ltd.'s holdings in Supernus Pharmaceuticals were worth $718,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Barclays PLC increased its stake in Supernus Pharmaceuticals by 88.3% in the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company's stock worth $3,393,000 after buying an additional 51,005 shares during the period. Segall Bryant & Hamill LLC bought a new position in Supernus Pharmaceuticals in the third quarter worth approximately $791,000. Geode Capital Management LLC raised its position in Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company's stock valued at $46,218,000 after purchasing an additional 74,438 shares in the last quarter. Franklin Resources Inc. grew its position in shares of Supernus Pharmaceuticals by 7.6% during the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company's stock worth $987,000 after buying an additional 2,121 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Supernus Pharmaceuticals by 40.6% during the third quarter. JPMorgan Chase & Co. now owns 253,396 shares of the specialty pharmaceutical company's stock valued at $7,901,000 after buying an additional 73,118 shares during the period.

Supernus Pharmaceuticals Stock Up 0.2 %

Shares of Supernus Pharmaceuticals stock traded up $0.09 during trading on Wednesday, reaching $40.09. The company's stock had a trading volume of 127,296 shares, compared to its average volume of 354,402. The business has a 50 day moving average price of $37.24 and a 200-day moving average price of $34.66. The company has a market capitalization of $2.21 billion, a P/E ratio of 37.44 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, beating analysts' consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The business had revenue of $175.70 million for the quarter, compared to analyst estimates of $157.35 million. During the same quarter last year, the company earned ($0.29) earnings per share. The business's revenue for the quarter was up 14.2% compared to the same quarter last year. Research analysts predict that Supernus Pharmaceuticals, Inc. will post 2.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Piper Sandler reaffirmed a "neutral" rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Cowen restated a "buy" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Finally, Cantor Fitzgerald assumed coverage on Supernus Pharmaceuticals in a research report on Monday, January 6th. They set an "overweight" rating and a $57.00 price target for the company.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 700 shares of the stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the sale, the vice president now directly owns 10,149 shares of the company's stock, valued at approximately $402,103.38. This represents a 6.45 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jack A. Khattar sold 125,000 shares of the business's stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the transaction, the chief executive officer now directly owns 926,172 shares of the company's stock, valued at $33,971,988.96. The trade was a 11.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 154,913 shares of company stock valued at $5,687,914. 9.30% of the stock is currently owned by corporate insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.